Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis
详细信息 查看全文
- 作者：Koji Sasaki ; Elias J. Jabbour ; Farhad Ravandi ; Nicholas J. Short ; Deborah A. Thomas ; Guillermo Garcia-Manero ; Naval G. Daver ; Tapan M. Kadia ; Marina Y. Konopleva ; Nitin Jain ; Ghayas C. Issa ; Vicki Jeanis ; Haim G. Moore ; Rebecca S. Garris ; Naveen Pemmaraju ; Jorge E. Cortes ; Susan M. O'Brien and Hagop M. Kantarjian
- 刊名：Cancer
- 出版年：2016
- 出版时间：December 1, 2016
- 年：2016
- 卷：122
- 期：23
- 页码：3650-3656
- 全文大小：184K
- ISSN：1097-0142
文摘
The clinical efficacy of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HCVAD) plus ponatinib has not been compared with that of HCVAD plus dasatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in a randomized clinical trial.